Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104157 | 0.83 | — | — | |
| Trifluoroacetic Acid SCHEMBL23932396 | 0.81 | LMNA (0.36) | RAB9AKMT2A | |
| SCHEMBL21750445 | 0.78 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL12551200 | 0.74 | LMNA (0.32) | RAB9A | |
| SCHEMBL440668 | 0.74 | HSD17B10 (0.34) | HSD17B10 | |
| SCHEMBL357819 | 0.74 | RAB9A (0.34) | RAB9AKMT2A | |
| SCHEMBL180596 | 0.73 | — | — | |
| SCHEMBL141255 | 0.73 | HSD17B10 (0.44) | HSD17B10RAB9AKMT2A | |
| SCHEMBL12551207 | 0.72 | RAB9A (0.33) | RAB9AKMT2A | |
| SCHEMBL4370824 | 0.71 | ADRA2B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116648250-B | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2025-06-13 | — | — | CN | claimed |
| CN-118019742-A | Novel benzodiazepine derivatives as GABA Aγ1 PAM | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117957227-A | Pyridodiazepine derivatives as GABA Aγ1 PAM | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117881684-A | Novel cyclopenta-thieno-diazepine derivatives as GABAA gamma 1 PAM | 豪夫迈·罗氏有限公司 | 2024-04-12 | — | — | CN | claimed |
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | claimed |
| CN-116648250-A | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2023-08-25 | — | — | CN | claimed |
| EP-4138824-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | Anovia Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | claimed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | claimed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | claimed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | claimed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | claimed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | claimed |
| EP-0354787-B1 | Oxaspiro[2,5]octane derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-02-15 | — | — | EP | claimed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | claimed |
| EP-0565484-A2 | HIV-protease inhibiting morpholin- and thiomorpholin-4-ylamides | CIBA-GEIGY AG (CH) | 1993-10-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | HSD17B10 4498/4885RAB9A 3231/4885CYP1A2 4241/4885 |
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | HSD17B10 1064/4885RAB9A 3780/4885CYP1A2 423/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | HSD17B10 4498/4885RAB9A 3231/4885CYP1A2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.